Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022

BUY
$8.51 - $13.6 $18,985 - $30,341
2,231 Added 20.04%
13,361 $140,000
Q2 2022

Aug 15, 2022

BUY
$7.31 - $11.85 $81,360 - $131,890
11,130 New
11,130 $108,000
Q1 2022

May 16, 2022

SELL
$7.35 - $10.63 $74,676 - $108,000
-10,160 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.19 - $9.56 $42,570 - $97,129
10,160 New
10,160 $97,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.